TSP-1 and TGF-beta
The brochure describes Palmitoyl Tripeptide-5 as mimicking TSP-1 function through the KRFK sequence, with a concept of binding inactive TGF-beta and releasing active TGF-beta.
AMULYN Palmitoyl Tripeptide-5 (Pal-KVK) is a cosmetic signal peptide for firming skincare, wrinkle-care, beauty and haircare formulations. Request specs.
AMULYN Signal Peptide Ingredient
A high-purity cosmetic peptide powder and 1,000 ppm liquid option identified as Pal-Lys-Val-Lys-OH (Pal-KVK). Designed for B2B skincare, beauty and haircare formulation development with a source-documented collagen-pathway concept and in-vitro eln1 gene-expression reference.
Ingredient profile
Palmitoyl Tripeptide-5 is described in the supplied brochure as a signal peptide. Its sequence is Pal-Lys-Val-Lys-OH (Pal-KVK), with a documented CAS number of 623172-56-5, molecular formula C33H65N5O5 and molecular weight of 611.90 g/mol.
The brochure positions this ingredient for skincare, beauty and haircare products. For B2B development, select the powder or liquid format according to the required dosage, process, documentation and finished-product format.
Visual library
Replace the placeholders with your approved peptide powder, liquid, structure, laboratory, packaging and application images. Use owned or licensed visuals only.
Recommended image set: powder, liquid solution, peptide structure, laboratory, skincare cream, serum, mask, haircare product, filling line and export packaging.
Mechanism concept
The mechanism language below summarizes the supplied brochure. Confirm the current technical file and claim substantiation before using it in advertising or finished-product labels.
The brochure describes Palmitoyl Tripeptide-5 as mimicking TSP-1 function through the KRFK sequence, with a concept of binding inactive TGF-beta and releasing active TGF-beta.
The source document links the concept to production of type I, II and IV collagen and extracellular-matrix proteins. Treat this as an ingredient mechanism reference, not a guaranteed finished-product result.
The brochure states that the peptide can inhibit MMP1 and MMP3 activity and reduce the generation of IL-8 and TNF-alpha. Verify test conditions and regulatory suitability before publication.
In-vitro reference
The brochure presents an in-vitro gene-expression test. It does not provide human clinical data in the reviewed pages, so the results should be communicated as source-document test references.
The brochure reports an increase of approximately 29% compared with the normal control in the eln1 reference test.
The brochure reports an increase of approximately 20% compared with the normal control in the eln1 reference test.
The brochure reports an increase of approximately 22% compared with the normal control in the eln1 reference test.
Ask for the test method, raw data, controls, test material identity and current report before making a numerical marketing claim.
Technical profile
Use this table for initial B2B conversations. Request the current TDS, COA, SDS, safety data and regulatory documentation before approval.
| Field | Documented information | Publication note |
|---|---|---|
| Product name | Palmitoyl Tripeptide-5 / 棕榈酰三肽-5 | Do not confuse with Palmitoyl Tripeptide-1, Palmitoyl Tetrapeptide-7 or other palmitoyl peptides. |
| Sequence | Pal-Lys-Val-Lys-OH (Pal-KVK) | Confirm the current certificate or technical document for the commercial batch. |
| INCI | Palmitoyl Tripeptide-5 on pages 28 and 47 | Page 43 contains an inconsistent "Palmitoyl Dipeptide-5" listing. Confirm final INCI before publication. |
| CAS | 623172-56-5 | Listed on the product detail page in the supplied brochure. |
| Molecular formula | C33H65N5O5 | Confirm against the current specification. |
| Molecular weight | 611.90 g/mol | Confirm against the current specification. |
| Powder format | High-purity peptide powder | Numerical purity and powder addition level are not provided in the brochure. |
| Liquid format | 1,000 ppm Palmitoyl Tripeptide-5 solution | Confirm carrier, preservative system and commercial packaging. |
| Recommended addition | Liquid: 1.0%-5.0% | Do not transfer this liquid dosage to the powder. Powder use level is not provided. |
| Applications | Skincare, beauty and haircare products; firming and wrinkle-care concepts | Validate compatibility, stability, safety and claim support in the finished product. |
| Storage | Protected from light and moisture; sealed; refrigerated at 2-8°C; room-temperature transport possible | Confirm current logistics and storage instructions for the commercial format. |
| Packaging | __PACKAGING_TO_CONFIRM__ | The brochure does not provide a clear product-specific packaging size. |
| Patent information | CN 111004306 B; solution listing also shows ZL 2019 1 1412657.8 | Verify ownership, scope, validity and whether the information may be used in marketing materials. |
Important: the brochure contains an INCI naming inconsistency. Use the current supplier TDS, COA, SDS and applicable regulatory documentation as the final source of truth.
Product applications
Use the following modules to help buyers connect Palmitoyl Tripeptide-5 with their target finished-product categories.
Evaluate the peptide format in cream systems designed around firming, texture and wrinkle-care positioning.
Use the 1,000 ppm liquid as a starting point for dosage and compatibility discussion, subject to confirmed documentation.
Screen the powder or liquid format in mask concepts while checking pH, preservation, stability and process conditions.
Build a dedicated eye-care visual and technical brief only after confirming the intended application and claim support.
The brochure lists beauty and haircare products as application directions; validate the finished formula and target-market requirements.
Show the development workflow from ingredient weighing and dissolution to finished-product stability testing.
B2B development workflow
A practical workflow for buyers who need more than a raw-material name.
Choose high-purity powder or the listed 1,000 ppm liquid according to your production process, target dosage and documentation needs.
Confirm INCI, CAS, purity, carrier, storage, packaging, COA, SDS, safety data and current regulatory status.
Screen pH, compatibility, stability, preservation and final claim substantiation in the finished cosmetic product.
Responsible communication
FAQ
Palmitoyl Tripeptide-5 is a cosmetic signal peptide ingredient identified in the supplied brochure by the sequence Pal-Lys-Val-Lys-OH, also called Pal-KVK.
The supplied brochure lists CAS 623172-56-5 for Palmitoyl Tripeptide-5.
The brochure describes a high-purity peptide powder and a 1,000 ppm liquid format. It lists a 1.0%-5.0% recommended addition level for the liquid. Confirm powder purity and powder use level before formulation.
The brochure positions Palmitoyl Tripeptide-5 for skincare, beauty and haircare products, including firming and wrinkle-care concepts.
The reviewed brochure pages provide an in-vitro eln1 elastin-gene expression reference at 0.01%, 0.02% and 0.05%. They do not provide human clinical data.
Start a peptide sourcing discussion
For a relevant quotation and technical review, include powder or liquid preference, target application, expected use level, trial quantity, packaging requirement, destination market and required documents.
1208, Building B, Huixin 1BC, No. 1 Zhang Bayi Road, High-tech Zone, Xi'an, Shaanxi, China
0086-199 9282 1268
Copyright @ 2024 AMULYN Corp All rights reserved.
Technical Support | Site Map